FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,862,405 | -50.4% | 4,177,848 | -10.8% | 0.00% | -50.0% |
| Q2 2023 | $21,909,219 | -37.9% | 4,681,457 | -50.0% | 0.00% | 0.0% |
| Q1 2023 | $35,298,186 | +316.3% | 9,362,914 | +247.8% | 0.00% | +100.0% |
| Q4 2022 | $8,479,971 | -7.5% | 2,692,054 | -11.6% | 0.00% | 0.0% |
| Q3 2022 | $9,171,000 | +13.3% | 3,046,813 | -6.3% | 0.00% | 0.0% |
| Q2 2022 | $8,094,000 | -68.0% | 3,250,680 | -0.0% | 0.00% | -50.0% |
| Q1 2022 | $25,259,000 | +87.5% | 3,250,832 | +0.6% | 0.00% | +100.0% |
| Q4 2021 | $13,469,000 | -47.3% | 3,229,966 | +0.1% | 0.00% | -50.0% |
| Q3 2021 | $25,554,000 | -0.7% | 3,226,471 | +1.3% | 0.00% | 0.0% |
| Q2 2021 | $25,728,000 | -23.5% | 3,184,209 | +1.5% | 0.00% | -33.3% |
| Q1 2021 | $33,643,000 | -8.5% | 3,138,388 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $36,772,000 | -2.1% | 3,129,434 | +0.1% | 0.00% | -25.0% |
| Q3 2020 | $37,561,000 | -29.3% | 3,124,803 | +2.8% | 0.00% | -33.3% |
| Q2 2020 | $53,091,000 | – | 3,038,998 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |